Evaluation of cefquinome's efficacy in controlling avian colibacillosis and detection of its residues using high performance liquid chromatography (HPLC)

El-Tahawy, Amany O.; Said, Ahmed A.; Shams, Gamal; Hassan, Hazem; Hassan, Aziza M.; Amer, Shimaa A.; El‐Nabtity, Sameh M.

doi:10.1016/j.sjbs.2022.02.029

Cited by 4 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chemical structural formula of cefquinome is shown in Figure 1 . In contrast to second and third generation cephalosporins, chemical modification of the basic structure of cephalosporins provides the amphoteric nature of cefquinome, which can promote rapid penetration of biological membranes and improve bioavailability ( 16 , 17 ). Cefquinome is a veterinary specific drug that is used in veterinary clinics for the treatment of respiratory diseases in horses ( 18 ) and pneumonia in dogs ( 19 ).…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics and relative bioavailability study of two cefquinome sulfate intramammary infusions in cow milk

Li,

Yu,

Tang

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

In this study, two intramammary infusions of cefquinome sulfate were investigated for pharmacokinetics and bioavailability. Twelve lactating cows for each group were administered an effective dose of 75 mg/gland for cefquinome, with milk samples collected at various time intervals. The concentrations of cefquinome in milk at different times were determined by the UPLC-MS/MS method. Analyses of noncompartmental pharmacokinetics were conducted on the concentration of cefquinome in milk. Mean pharmacokinetic parameters of group A and group B following intramammary administration were as follows: AUClast 300558.57 ± 25052.78 ng/mL and 266551.3 ± 50654.85 ng/mL, Cmax 51786.35 ± 11948.4 ng/mL and 59763.7 ± 8403.2 ng/mL, T1/2 5.69 ± 0.62 h and 5.25 ± 1.62 h, MRT 7.43 ± 0.79 h and 4.8 ± 0.78 h, respectively. Pharmacokinetic experiments showed that the relative bioavailability of group B was 88.69% that of group A. From our findings, group B (3 g: 75 mg) shows a quicker drug elimination process than group A (8 g: 75 mg), which suggests that the withdrawal period for the new formulation may be shorter.

show abstract